 bat spit drug firm go market german firm whose main product derived saliva vampire bat looking raise 70m euro 91m â¼49m stock market firm paion said hoped sell 5 million share third firm 1114 euro share main drug desmoteplase based protein bat saliva protein stop blood clotting help bat drink victim could also used help stroke sufferer company share go sale later week scheduled start trading frankfurt stock exchange 10 february final price top range company could valued much 200m euro money raised spent largely developing company drug since desmoteplase already licensed one manufacturer forest laboratory